logo

For the Inventor, By the Inventor

Boulder, CO, United States of America

Miragen Therapeutics, Inc.

USPTO Granted Patents = 20

% Expired Patents = 100.0



Trademarks = 1

Forward Citations = 49

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Christina Marie Dalby (16 out of 16 patents)

silverMedal Rusty L Montgomery (10 out of 10 patents)

bronzeMedal Eva Van Rooij (9 out of 23 patents)

4.  Anita Seto (7 out of 7 patents)

5.  Aimee Jackson (5 out of 5 patents)

6.  Corrie Lynn Gallant-Behm (4 out of 4 patents)

7.  Kurt Vagle (4 out of 11 patents)

8.  William Marshall (3 out of 138 patents)

9.  David Rodman (3 out of 3 patents)

10.  Xuan Beatty (3 out of 3 patents)

11.  Kathryn H Hutnick (3 out of 3 patents)

12.  Eric N Olson (1 out of 54 patents)

13.  Thomas G Hullinger (1 out of 1 patent)

14.  Chad Grueter (1 out of 1 patent)

15.  Eva Van Rooij (1 patent)


20 patents:

1. 10337005 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2019-07-02),
2. 10316318 - Oligonucleotide compositions and uses thereof (2019-06-11),
3. 10280422 - MiR-92 inhibitors and uses thereof (2019-05-07),
4. 10144930 - Inhibitors of MYH7B and uses thereof (2018-12-04),
5. 10030042 - Synthesis of bicyclic nucleosides (2018-07-24),
6. 10011833 - Bridged bicyclic nucleosides (2018-07-03),
7. 9994852 - Oligonucleotide compositions and uses thereof (2018-06-12),
8. 9994847 - miR-29 mimics and uses thereof (2018-06-12),
9. 9885042 - miR-92 inhibitors and uses thereof (2018-02-06),
10. 9803202 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2017-10-31),
11. 9771585 - miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) (2017-09-26),
12. 9752144 - Inhibitors of MYH7B and uses thereof (2017-09-05),
13. 9752143 - Locked nucleic acid inhibitor of miR-145 and uses thereof (2017-09-05),
14. 9428749 - Control of whole body energy homeostasis by microRNA regulation (2016-08-30),
15. 9416360 - Base modified oligonucleotides (2016-08-16),
Company Overview
Miragen Therapeutics, Inc. is a biotechnology company based in Boulder, Colorado, focused on the development of innovative therapies for serious diseases. The company specializes in the discovery and advancement of microRNA-based treatments, leveraging its proprietary platform to address unmet medical needs in areas such as oncology and cardiovascular diseases. Through its research, Miragen aims to harness the potential of microRNAs to create targeted therapies that can significantly improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

20 Patents

#64 in Boulder, CO

#331 in Colorado

#16,409 in US

#31,295 in the World

Boulder, CO (US)
Boulder, CO, United States of America

Miragen Therapeutics, Inc.

Forward Citations = 49

14 inventors:

goldMedal Christina Marie Dalby (16 out of 16 patents)

silverMedal Rusty L Montgomery (10 out of 10 patents)

bronzeMedal Eva Van Rooij (9 out of 23 patents)

4.  Anita Seto (7 out of 7 patents)

5.  Aimee Jackson (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Miragen Therapeutics, Inc.. Retrieved from https://idiyas.com/company/miragen-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…